Literature DB >> 31158080

External Validation of Models Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients.

Tom A Hueting1, Erik B Cornel2, Diederik M Somford3, Hanneke Jansen4, Jean-Paul A van Basten3, Rick G Pleijhuis5, Ruben A Korthorst6, Job A M van der Palen7, Hendrik Koffijberg8.   

Abstract

BACKGROUND: Multiple statistical models predicting lymph node involvement (LNI) in prostate cancer (PCa) exist to support clinical decision-making regarding extended pelvic lymph node dissection (ePLND).
OBJECTIVE: To validate models predicting LNI in Dutch PCa patients. DESIGN, SETTING, AND PARTICIPANTS: Sixteen prediction models were validated using a patient cohort of 1001 men who underwent ePLND. Patient characteristics included serum prostate specific antigen (PSA), cT stage, primary and secondary Gleason scores, number of biopsy cores taken, and number of positive biopsy cores. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Model performance was assessed using the area under the receiver operating characteristic curve (AUC). Calibration plots were used to visualize over- or underestimation by the models. RESULTS AND LIMITATIONS: LNI was identified in 276 patients (28%). Patients with LNI had higher PSA, higher primary Gleason pattern, higher Gleason score, higher number of nodes harvested, higher number of positive biopsy cores, and higher cT stage compared to patients without LNI. Predictions generated by the 2012 Briganti nomogram (AUC 0.76) and the Memorial Sloan Kettering Cancer Center (MSKCC) web calculator (AUC 0.75) were the most accurate. Calibration had a decisive role in selecting the most accurate models because of overlapping confidence intervals for the AUCs. Underestimation of LNI probability in patients had a predicted probability of <20%. The omission of model updating was a limitation of the study.
CONCLUSIONS: Models predicting LNI in PCa patients were externally validated in a Dutch patient cohort. The 2012 Briganti and MSKCC nomograms were identified as the most accurate prediction models available. PATIENT
SUMMARY: In this report we looked at how well models were able to predict the risk of prostate cancer spreading to the pelvic lymph nodes. We found that two models performed similarly in predicting the most accurate probabilities.
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  External validation; Lymph node involvement; Nomograms; Pelvic lymph node dissection; Prediction models; Prostate cancer

Mesh:

Year:  2018        PMID: 31158080     DOI: 10.1016/j.euo.2018.04.016

Source DB:  PubMed          Journal:  Eur Urol Oncol        ISSN: 2588-9311


  8 in total

1.  Preoperative endogenous testosterone density predicts disease progression from localized impalpable prostate cancer presenting with PSA levels elevated up to 10 ng/mL.

Authors:  Antonio Benito Porcaro; Alberto Bianchi; Giovanni Mazzucato; Sebastian Gallina; Emanuele Serafin; Alessandro Tafuri; Clara Cerrato; Andrea Panunzio; Stefano Vidiri; Damiano D'Aietti; Rossella Orlando; Davide Brusa; Matteo Brunelli; Salvatore Siracusano; Maria Angela Cerruto; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2022-10-05       Impact factor: 2.266

2.  68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer.

Authors:  Snir Dekalo; Jonathan Kuten; Jeffrey Campbell; Ishai Mintz; Yuval Bar-Yosef; Daniel Keizman; David Sarid; Einat Even-Sapir; Ofer Yossepowitch; Roy Mano
Journal:  Can Urol Assoc J       Date:  2022-07       Impact factor: 2.052

3.  68Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer.

Authors:  Daniela A Ferraro; Urs J Muehlematter; Helena I Garcia Schüler; Niels J Rupp; Martin Huellner; Michael Messerli; Jan Hendrik Rüschoff; Edwin E G W Ter Voert; Thomas Hermanns; Irene A Burger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-14       Impact factor: 9.236

4.  Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer.

Authors:  Elio Mazzone; Paolo Dell'Oglio; Nikos Grivas; Esther Wit; Maarten Donswijk; Alberto Briganti; Fijs Van Leeuwen; Henk van der Poel
Journal:  J Nucl Med       Date:  2021-02-05       Impact factor: 10.057

5.  External Validation and Comparison of Two Nomograms Predicting the Probability of Lymph Node Involvement in Patients subjected to Robot-Assisted Radical Prostatectomy and Concomitant Lymph Node Dissection: A Single Tertiary Center Experience in the MRI-Era.

Authors:  Nicola Frego; Marco Paciotti; Nicolò Maria Buffi; Davide Maffei; Roberto Contieri; Pier Paolo Avolio; Vittorio Fasulo; Alessandro Uleri; Massimo Lazzeri; Rodolfo Hurle; Alberto Saita; Giorgio Ferruccio Guazzoni; Paolo Casale; Giovanni Lughezzani
Journal:  Front Surg       Date:  2022-02-25

6.  External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer.

Authors:  Daimantas Milonas; Zilvinas Venclovas; Tim Muilwijk; Mindaugas Jievaltas; Steven Joniau
Journal:  Cent European J Urol       Date:  2020-03-03

7.  Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold.

Authors:  Zilvinas Venclovas; Tim Muilwijk; Aivaras J Matjosaitis; Mindaugas Jievaltas; Steven Joniau; Daimantas Milonas
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

Review 8.  Pelvic lymph node dissection in high-risk prostate cancer.

Authors:  Luciano Haiquel; Xavier Cathelineau; Rafael Sanchez-Salas; Petr Macek; Fernando Secin
Journal:  Int Braz J Urol       Date:  2022 Jan-Feb       Impact factor: 1.541

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.